EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Released
Released
Announcement PDF
Cynata Therapeutics Limited
ABN – 98 104 037 372
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia
T: +613 7067 6940
E: info@cynata.com
www.cynata.com
ASX ANNOUNCEMENT 3 June 2026
EMA PDCO Positive Opinion on CYP-001 Paediatric
Investigation Plan
Melbourne, Australia; 3 June 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the
“Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has received a Positive
Opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA), on the Paediatric
Investigation Plan (PIP) for CYP-001 in acute graft versus host disease (aGvHD).
Key Highlights:
• An agreed PIP1
is required before commencement of a Phase 3 clinical trial in the European Union (EU),
regardless of whether the Phase 3 trial will include adults, children or both.
• The PDCO has agreed to the Company’s proposed PIP, which will involve a single randomised controlled
Phase 2/3 clinical trial of CYP-001 in ~72 aGvHD patients aged from 28 days to 18 years.
• The Company plans to commence a Phase 3 clinical trial in adults initially. After completion of the
primary analysis of the adult Phase 3 trial, the Company plans to commence the paediatric clinical trial.
CYP-001 is Cynata’s Cymerus™ iPSC2
-derived MSC3
product for intravenous use, which is designed to modulate
the immune system and improve both response rates and survival outcomes in aGvHD.
aGvHD is a serious and often life-threatening complication of bone marrow transplantation and similar
procedures,4
where the donor’s immune cells (the graft) attack the recipient’s tissues (the host). aGvHD affects
up to 50% of patients who receive transplants from other donors. Standard first-line treatment with steroids fails
in around one-half of all aGvHD cases, which are known as “steroid-resistant” or steroid-resistant aGvHD (SR-
aGvHD) cases. Historical two-year survival rates in patients with SR-aGvHD are less than 20%.5
A Phase 1 trial in adults with SR-aGvHD delivered an 87% Overall Response Rate, a 53% Complete Response
Rate, and 60% two-year overall survival, with no serious adverse events or safety concerns related to CYP-001
treatment. This ground-breaking trial led to two publications in the prestigious journal Nature Medicine.6,7
In March this year, the primary evaluation period was completed in the Company's Phase 2 trial of CYP-001 in
adults with high risk aGvHD. A total of 65 participants were enrolled across clinical centres in Australia, the USA
and Europe, randomised to receive either steroids plus CYP-001 or steroids plus placebo. The primary endpoint
is Overall Response Rate at Day 28, with results anticipated in late June or early July 2026.
Subject topositivedata from the Phase 2 trial in adults,theCompany’sdevelopment plan forCYP-001 for aGvHD
currently envisages a single Phase 3 trial in adults, followed by a separate Phase 2/3 trial in children. In both
trials, it is anticipated that patients will be randomised to receive either steroids plus CYP-001 or steroids plus
placebo. The PDCO has now agreed with this plan, including with the proposed timing of the paediatric trial,
which means that the Marketing Authorisation Application for adults could be submitted while the paediatric
trial is still ongoing. The PDCO’s Positive Opinion will now be sent to the European Commission for formal
adoption.
Nuket Desem, Cynata’s Director of Regulatory and Scientific Affairs, said:
"Gaining EMA approval of our PIP is a key step towards late-phase clinical development and commercialisation
of CYP-001 in the EU, for both adults and children. Europe is a very important market for us in general, and for
aGvHD in particular. aGvHD is more common in Europe than in any other region, with approximately twice as
many cases as in the USA,8
and there are currently no EMA-approved cell-based therapies for the treatment of
aGvHD in any age group.”
-ENDS-
Cynata Therapeutics Limited
ABN – 98 104 037 372
Level 3, 100 Cubitt Street
Cremorne
VIC 3121
Australia
T: +613 7067 6940
E: info@cynata.com
www.cynata.com
Authorised for release by Dr Kilian Kelly, CEO & Managing Director
CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the
development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the
challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic
manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain
tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional
methods.
Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1
clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials
are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing
kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™
technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma,
heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
1
In accordance with the EU Paediatric Regulation (Regulation (EC) No 1901/2006)
2
iPSC = induced pluripotent stem cell.
3
MSC = mesenchymal stem (or stromal) cell.
4
Technically referred to as allogeneic haematopoietic stem cell transplantation (HSCT).
5
Westin JR, et al. Adv Hematol. 2011;2011:601953
6
Bloor AJC, et al. Nat Med. 2020;26:1720–1725
7
Kelly K, et al. Nat Med. 2024;30:1556–1558
8
aGvHD is a consequence of allogeneic haematopoietic stem cell transplantation (HSCT). >20,000 allogeneic HSCTs are performed per
annum in Europe (Passweg JR et al, Bone Marrow Transplant. 2025;60:519–528) compared to <10,000 in the USA (Spellman SR et al,
Transplant Cell Ther. 2025;31(8):505-532).
Share your feedback
Discover